Zimbabwe has declined a substantial US health deal worth 367 million US dollars (£272m) spanning five years over Washington's request for confidential biological samples.
The decision was revealed following a government memo from December was leaked, indicating that Head of State Emmerson Mnangagwa believed the agreement was "unbalanced".
A government spokesperson has since clarified that the US was seeking health data for research and commercial gain but was not willing to guarantee the resulting advantages from any future medical innovations.
"We must now begin the difficult and regrettable task of winding down our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had furnished more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has appealed for further talks to find a agreement agreeable to both sides so the country's critical HIV programme can be sustained.
Wider Implications
Zimbabwe's decision follows a comparable case in Kenya, where a high court suspended a related deal with the US after legal challenges were raised about the security of citizens' health data.
Since resuming office recently, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
The agency had overseen assistance for the American government, but Trump argued its spending was "inefficient" and his government was seeking direct bilateral deals to enhance openness and responsibility.
As per reports, Sixteen nations in Africa have so far agreed to these new health pacts, constituting over $18.3bn of fresh investment.
Specifics of the Declined Deal
The money for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this partnership might have yielded immense benefits for the people of Zimbabwe, particularly the 1.2 million presently receiving antiretroviral therapy via US-supported initiatives," the Ambassador said.
However, official spokesman Nick Mangwana maintained the proposed deal was "unfair".
"Zimbabwe was being asked to share its biological resources and data for a long time, without any corresponding guarantee of benefiting from any scientific breakthroughs – such as new medicines or tests – that could result from that provided information," he stated.
"Effectively, our nation would provide the basic resources for medical research with no assurance that the final treatments would be accessible to our population should a new disease outbreak arise."
National Interest and International Frameworks
He also pointed out that the US's withdrawal from the global health body and its pursuit of bilateral deals were undermining structures already established via the international health agency.
Mangwana cited its Pandemic Benefit-Sharing system designed to manage potential pandemics.
"This system is designed to guarantee that when a nation contributes its samples, the benefits – including medicines and cures – are shared equitably, not commercialised solely by those with the resources to develop them."
These objections regarding the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We welcome ongoing discussions with our American counterparts on how future co-operation could be designed in a way that respects the independence and dignity of both nations."
Medical Community Response
A leading public health body said it understood the government's concerns, but recommended that negotiations need to persist considering much of the nation's Aids initiatives were funded by foreign aid.
"If specific concerns exist, including those involving information security or agreement terms, these can frequently be resolved via technical clarification and mutually agreed protections," the group said.
The halted deal highlights the continuing challenges between accepting much-needed foreign assistance and safeguarding a country's data in an increasingly interconnected world.